News Releases

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on January...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's...

The Quest AD-Detect® blood-based test panels deliver confirmatory accuracy, potentially supporting reduced reliance on PET-imaging confirmation SECAUCUS, N.J., Oct. 27, 2025 /PRNewswire/ -- Two...

Third quarter revenues of $2.82 billion, up 13.1% from 2024 Third quarter reported diluted earnings per share ("EPS") of $2.16, up 8.5% from 2024; and adjusted diluted EPS of $2.60, up 13.0% from 2024

Blood test to aid cancer treatment and recurrence monitoring now available from a German lab for potentially faster results HAMBURG, Germany, Oct. 17, 2025 /PRNewswire/ -- MVZ HPH Institute for...

Together with New Oura Ring 4 Charging Case, Multi-Ring Support, and In-App Bloodwork with Health Panels, the Ceramic Collection Gives Members More Freedom, Style, and Deeper Health Insights SAN...

Over 350,000 members have joined the waitlist since May, underscoring the excitement for one product that can pair blood biomarkers with 24/7 wearable data BOSTON, MA — [September 30, 2025] —...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report third quarter 2025 financial results on Tuesday, October 21, 2025,...

With the most comprehensive Epic integration by a laboratory provider, collaboration will streamline and strengthen the customer experience for health systems, hospitals, independent providers and...

Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with the Rutgers Cancer Institute to evaluate the use of Haystack MRD®, a highly sensitive...

Implementation will enable users to purchase, schedule appointments for testing, and receive results of lab tests performed by Quest within the WHOOP app, supporting access to deeper health and...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the...

New Service Empowers Clinicians with Personalized Insights from Coriell Life Sciences to Optimize Prescribing Across Specialties SECAUCUS, N.J., Sept. 4, 2025 /PRNewswire/ -- Quest Diagnostics...

Majority of fentanyl positives also contain other drugs, with co-positivity with marijuana doubling since 2020 SECAUCUS, N.J., Sept. 2, 2025 /PRNewswire/ -- The percentage of employees in the...

Parties to build state-of-the-art laboratory in Southfield to serve physicians and patients across the state Quest will also manage Corewell Health's 21 hospital labs SOUTHFIELD, Mich. and GRAND...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on October...

Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with Mass General Brigham investigators at Massachusetts Eye and Ear and Massachusetts General...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its previously announced acquisition of select clinical testing assets of...

New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic causes of disease BOSTON, July 29, 2025 /PRNewswire/ -- Athena Diagnostics, the specialty neurology...

Second quarter revenues of $2.76 billion, up 15.2% from 2024 Second quarter reported diluted earnings per share ("EPS") of $2.47, up 21.7% from 2024; and adjusted diluted EPS of $2.62, up 11.5%...

Diagnostic testing for emerging infectious disease associated with severe neurological affects SECAUCUS, N.J., July 15, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic...

Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect™ product line for assessing symptomatic patients SECAUCUS, N.J.,...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today published its 2024 Corporate Responsibility Report. The theme of the report, Care Starts Here, reflects the...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report second quarter 2025 financial results on Tuesday, July 22, 2025, before the...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) designed...

Quest's second "Know Your Health" survey explores Americans' perceptions and priorities on their well-being in 2025 Nearly one-third of Americans say their doctors/HCPs do not take the time to...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on July 21,...

More than 3 in 4 oncologists (76%) feel they are seeing more advanced cancers, and of these, 75% believe that screening barriers are the leading cause, although nearly one-third (32%) cite...

First quarter revenues of $2.65 billion, up 12.1% from 2024 First quarter reported diluted earnings per share ("EPS") of $1.94, up 12.8% from 2024; and adjusted diluted EPS of $2.21, up 8.3% from 2024

In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology with greater than 90% sensitivity...

Providers in the United States may now order the FDA-cleared HPV self-collection solution for their patients to use in their offices or other healthcare settings, with goal to reduce barriers to...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2025 financial results on Tuesday, April 22, 2025, before the...

Provides long-term outlook beyond 2025: Revenues expected to grow at 4-5% compound annual growth rate (CAGR); adjusted diluted earnings per share (EPS) expected to grow at 7-9% CAGR Reaffirms...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a collaboration with Google Cloud to streamline Quest's data management, improve data analytics, and...

Fresenius Medical Care (XETRA: FME; NYSE: FMS), the world's leading provider of products and services for individuals with renal disease, and Quest Diagnostics (NYSE: DGX), a leading provider of...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will host an Investor Day for institutional investors and financial analysts in New York City on Thursday,...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been selected as one of the 2025 World's Most Admired Companies™ by Fortune®...

Fourth quarter revenues of $2.62 billion, up 14.5% from 2023 Fourth quarter reported diluted earnings per share ("EPS") of $1.95, up 14.7% from 2023; and adjusted diluted EPS of $2.23, up 3.7%...

Physicians and patients to benefit from access to Quest's industry-leading test menu and broad health plan relationships in Ohio SECAUCUS, N.J. and CLEVELAND, Jan. 27, 2025 /PRNewswire/ -- Quest...

Quality and regulatory veteran of Getinge, BD and J&J joins the Quest Diagnostics executive team SECAUCUS, N.J., Jan. 8, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report fourth quarter and full year 2024 financial results on Thursday, January 30,...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance...

New service takes the guesswork out of achieving one's health goals by empowering individuals to pair Quest lab results with personalized coaching SECAUCUS, N.J,, Dec. 3, 2024 /PRNewswire/ --...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on January...

Quest to develop laboratory tests and support public health reporting and laboratory readiness for CDC's preparedness strategy; Company to introduce clinical testing for avian flu later this month...

Third quarter revenues of $2.49 billion, up 8.5% from 2023 Third quarter reported diluted earnings per share ("EPS") of $1.99, up 1.5% from 2023; and adjusted diluted EPS of $2.30, up 3.6% from...

The Inter-Organization Cancer Genetics Clinical Evidence Coalition (INTERACT) applauds the National Comprehensive Cancer Network (NCCN) for recent updates to its Genetic/Familial High-Risk...